Autres langues Orexo AB

Actions

ORX

SE0000736415

Produits pharmaceutiques

Marché Fermé - Nasdaq Stockholm 18:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
13,28 ^SEK	-0,90%		-12,29%	-55,88%

10/09	Orexo obtient un financement supplémentaire de 3 millions de dollars pour son traitement d'urgence contre les surdoses d'opioïdes	MT
10/09	Orexo reçoit 3 millions de dollars supplémentaires de la BARDA pour l'OX390	FW

Autres langues

10/09	Orexo Secures Additional $3 Million Funding for Opioid Overdose Rescue Medicine
10/09	BARDA Supports Contract Modification extending the initial Development stage for the OX390 project to end of 2027
02/09	Orexo's Finance Chief Plans Exit in December
01/09	Fredrik Järrsten resigns as CFO of Orexo AB
01/09	Orexo AB Reaches Non-Binding Agreement in Principle to Settle Investigation by US Department of Justice
01/09	Orexo AB Announces Resignation of Fredrik Järrsten as Chief Financial Officer, Effective December 2026
31/08	Orexo: Highlights from DNB Carnegie’s Micro Cap Day
31/08	Orexo: Reaches a non-binding settlement with DOJ
31/08	Orexo Reaches Preliminary $4 Million Settlement for US Department of Justice Probe
31/08	Orexo reaches non-binding agreement in principle to settle investigation by US Department of Justice
17/07	Orexo: Weak Q2, with potential H2 catalysts nearing – Q2 review
16/07	Orexo AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026
16/07	Orexo AB Opens the Process to Look at Financing Opportunities
16/07	Orexo : Audiocast (engelska)
16/07	Orexo Q2 2026 Interim Report
09/06	Orexo AB Announces Appointment of Raheleh Nassaji as Senior Vice President Business Development
09/06	Orexo appoints Raheleh Nassaji as SVP Business Development, strengthening its focus on new partnerships
19/05	Orexo announces positive outcome from an in-vivo study of Ox390
19/05	Orexo AB Announces Positive Outcome from In-Vivo Study of OX390
19/05	Orexo: Promising early-stage data
19/05	Orexo announces positive pre-clinical data for nasal atipamezole using Amorphox technology
19/05	Orexo announces positive outcome from an in-vivo study of OX390
07/05	Report from Orexo AB’s annual general meeting May 7 2026
29/04	Orexo: Better visibility, few near-term catalysts – Q1 review
28/04	Orexo : Earnings Call Q1 2026 (engelska)